Randomized, Double-blind, Active -Controlled Trial to Assess Safety and Immunogenicity of Solvay's Cell-derived Influenza Vaccine, Including Revaccination, in Elderly Subjects

Trial Profile

Randomized, Double-blind, Active -Controlled Trial to Assess Safety and Immunogenicity of Solvay's Cell-derived Influenza Vaccine, Including Revaccination, in Elderly Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Abbott Laboratories; Solvay
  • Most Recent Events

    • 04 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Aug 2010 Planned end date changed from 1 May 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.
    • 28 Jan 2010 Actual patient number (622) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top